RNA interference (RNAi) has considerable potential as a therapeutic strategy, but the development of efficient in vivo RNA delivery methods remains challenging. To this end, we designed and synthesized chemically modified interfering nanoparticles (iNOPs) composed of functionalized poly-l-lysine dendrimers modified with reducible spacers to facilitate release of small interfering RNAs (siRNAs) in vivo. We show that the novel siRNA-iNOP complexes mediate efficient gene-specific RNAi in cultured cells and in mice, where they display enhanced tissue-targeting capabilities. At a clinically feasible dose of 1 mg kg-1, apolipoprotein B (apoB) siRNA-iNOP complexes achieved ∼40-45% reduction of liver apoB mRNA and plasma apoB protein levels within 48 h of administration to mice, without apparent toxicity. Collectively, these findings demonstrate that siRNA delivery by the modified reducible iNOPs can provide a clinically significant and potentially tissue-specific new approach for RNAi therapy. © 2013 American Chemical Society.
CITATION STYLE
Baigude, H., Su, J., McCarroll, J., & Rana, T. M. (2013). In vivo delivery of RNAi by reducible interfering nanoparticles (iNOPs). ACS Medicinal Chemistry Letters, 4(8), 720–723. https://doi.org/10.1021/ml4001003
Mendeley helps you to discover research relevant for your work.